Papaconstantinou Dimitris, Georgalas Ilias, Kourtis Nikolaos, Pitsas Christos, Karmiris Efthimios, Koutsandrea Chrysanthi, Ladas Ioannis, Georgopoulos Gerasimos
Department of Ophthalmology, "G Gennimatas" Hospital of Athens, University of Athens, Athens, Greece.
Clin Ophthalmol. 2009;3:227-30. doi: 10.2147/opth.s5053. Epub 2009 Jun 2.
The purpose of this prospective study was to evaluate the efficacy in intraocular pressure (IOP) control and the tolerance of a topically administered fixed combination of timolol-brimonidine in 50 patients with ocular hypertension and primary open-angle glaucoma.
After determining a baseline IOP, the fixed combination timolol-brimonidine was used twice daily for two months, while IOP, ophthalmic signs, and/or symptoms were monitored.
The mean IOP value was decreased from 23.09 mm Hg (+/-1.98 SD) to 17.46 mm Hg (+/-1.47 SD) during the 1st month (paired Student's t test = 9.88 kappaalphaiota p < 0.001), and to 17.51 mm Hg (+/-1.43 SD) in the 2nd month. Between the 1st and 2nd month, no statistical difference was observed (paired Student's t test = 0.02 kappaalphaiota p > 0.1). In 8% of the patients during the 1st month and 10% of patients in the 2nd month, some ophthalmic signs were observed, while only mild ophthalmic symptoms were reported in 6% and 8% of the patients, respectively.
In conclusion, the fixed combination of timolol-brimonidine has a satisfactory IOP-lowering effect without any serious side effects due to the topical use.
本前瞻性研究旨在评估局部应用噻吗洛尔-溴莫尼定固定复方制剂对50例高眼压症和原发性开角型青光眼患者的眼压控制效果及耐受性。
在确定基线眼压后，噻吗洛尔-溴莫尼定固定复方制剂每日使用两次，持续两个月，同时监测眼压、眼部体征和/或症状。
第1个月时，平均眼压值从23.09 mmHg（±1.98标准差）降至17.46 mmHg（±1.47标准差）（配对t检验=9.88，P<0.001），第2个月时降至17.51 mmHg（±1.43标准差）。在第1个月和第2个月之间，未观察到统计学差异（配对t检验=0.02，P>0.1）。第1个月有8%的患者出现一些眼部体征，第2个月有10%的患者出现；分别有6%和8%的患者报告仅有轻微的眼部症状。
总之，噻吗洛尔-溴莫尼定固定复方制剂具有令人满意的降眼压效果，局部使用无任何严重副作用。
